Search hospitals

>

Ohio

>

Canton

Gabrail Cancer Center

Claim this profile

Canton, Ohio 44718

Global Leader in Lung Cancer

Global Leader in Cancer

Conducts research for Non-Small Cell Lung Cancer

Conducts research for Solid Tumors

Conducts research for Pancreatic Cancer

328 reported clinical trials

7 medical researchers

Photo of Gabrail Cancer Center in CantonPhoto of Gabrail Cancer Center in CantonPhoto of Gabrail Cancer Center in Canton

Summary

Gabrail Cancer Center is a medical facility located in Canton, Ohio. This center is recognized for care of Lung Cancer, Cancer, Non-Small Cell Lung Cancer, Solid Tumors, Pancreatic Cancer and other specialties. Gabrail Cancer Center is involved with conducting 328 clinical trials across 281 conditions. There are 7 research doctors associated with this hospital, such as Nashat Gabrail, M.D., Gabrail Nashat, Ga Nashat, Doctorate, and Nashal Gabrail, MD.

Area of expertise

1

Lung Cancer

Global Leader

Gabrail Cancer Center has run 84 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
metastatic
2

Cancer

Global Leader

Gabrail Cancer Center has run 78 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
EGFR positive

Top PIs

Clinical Trials running at Gabrail Cancer Center

Cancer

Lung Cancer

Breast Cancer

Pancreatic Cancer

Myelofibrosis

Solid Tumors

Non-Small Cell Lung Cancer

Follicular Lymphoma

Ovarian Cancer

Endometrial Cancer

Image of trial facility.

Continued Darolutamide Treatment

for Cancer

This trial continues darolutamide treatment for patients who were part of a previous study and are believed to benefit from it. Darolutamide helps by blocking hormones that can make cancer cells grow. Patients will keep taking the same dosage and visit their doctors regularly. Darolutamide has been shown to slow cancer spread and improve survival in patients with nonmetastatic castration-resistant prostate cancer.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Sigvotatug Vedotin + Pembrolizumab

for Non-Small Cell Lung Cancer

The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's immune responses under control. The study is seeking for participants who: * Are confirmed to have NSCLC (Stage 3 or 4). * Have PD-L1 levels in more than 50% of the cancer cells. All participants in this study will receive pembrolizumab at the study clinic once every 6 weeks as an intravenous (IV) infusion (give directly into a vein). In addition, half of the participants will also receive Sigvotatug Vedotin once every 2 weeks as an IV infusion in addition to receiving pembrolizumab. Participants may receive pembrolizumab for up to about two years. Those participants taking Sigvotatug Vedotin can continue until their NSCLC is no longer responding. The study team will monitorsee how each participant is doing with the study treatment during regular visits at the clinic.

Recruiting

2 awards

Phase 3

6 criteria

Image of trial facility.

Bria-IMT + CPI

for Advanced Breast Cancer

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.

Recruiting

2 awards

Phase 3

6 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Gabrail Cancer Center?

Where is Gabrail Cancer Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does Gabrail Cancer Center accept?

What awards or recognition has Gabrail Cancer Center received?